77307-50-7

Usage

Uses

Used in Pharmaceutical Industry:
SL0101 is used as a potent and selective inhibitor of p90 Rsk for targeting the RSK2 enzyme, which plays a role in various cellular processes. Its selectivity allows for specific inhibition without affecting upstream kinases such as MEK, Raf, or PKC.
Used in Cancer Research:
SL0101 is used in cancer research to study the effects of inhibiting RSK2 on the proliferation of cancer cells, such as MCF-7 breast cancer cells. At 100 μM, SL0101-1 arrests cells in the G1 phase of the cell cycle, providing insights into the potential use of RSK2 inhibition in cancer treatment.
Used in Signal Transduction Research:
SL0101 is used in signal transduction research to investigate the role of RSK2 in intracellular signaling events associated with angiotensin II-induced tyrosine kinase activation. A concentration of 30 μM attenuates angiotensin II-induced cell proliferation, offering a tool to study the underlying mechanisms of this process.

Biological Activity

Selective inhibitor of p90 ribosomal S6 kinase (RSK) (IC 50 = 89 nM for RSK2). Does not inhibit upstream kinases such as MEK, Raf and PKC.? Inhibits the growth of MCF-7 human breast cancer cells with no effect on the normal breast cell line.

InChI:InChI=1/C25H24O12/c1-10-21(34-11(2)26)24(35-12(3)27)20(32)25(33-10)37-23-19(31)18-16(30)8-15(29)9-17(18)36-22(23)13-4-6-14(28)7-5-13/h4-10,20-21,24-25,28-30,32H,1-3H3/t10-,20+,21?,24?,25?/m0/s1

Synthetic route

5,7-bis(benzyloxy)-2-(4-benzyloxyphenyl)-3-[3,4-di-O-acetyl-2-O-benzyl-α-L-rhamnopyranosyloxy]-4H-chromen-4-one (849938-27-8) → Kaempferol-3-O-(3,4-O-diacetyl-α-L-rhamnopyranoside) (77307-50-7)

Conditions	Yield
With hydrogen; palladium dihydroxide In tetrahydrofuran; methanol for 1h;	94%
With hydrogen; palladium hydroxide on carbon In tetrahydrofuran; methanol for 1h;	94%

(2S,3S,4S,5R,6S)-6-((5,7-bis(benzyloxy)-2-(4-(benzyloxy)phenyl)-4-oxo-4H-chromen-3- yl)oxy)-5-hydroxy-2-methyltetrahydro-2H-pyran-3,4-diyl diacetate (916069-08-4) → Kaempferol-3-O-(3,4-O-diacetyl-α-L-rhamnopyranoside) (77307-50-7)

Conditions	Yield
With 1,8-diazabicyclo[5.4.0]undec-7-ene In toluene at 0℃; for 1h;	91%

tert-butyl ((2S,6S)-6-methyl-5-oxo-5,6-dihydro-2H-pyran-2-yl) carbonate (865484-73-7) → Kaempferol-3-O-(3,4-O-diacetyl-α-L-rhamnopyranoside) (77307-50-7)

Conditions

Yield

Multi-step reaction with 7 steps 1.1: 85 percent / PPh3 / Pd2(dba)3*CHCl3 / CH2Cl2 / 3 h / 0 °C 2.1: 73 percent / NaBH4 / CH2Cl2; methanol / 3 h / -78 °C 3.1: 156 mg / pyridine; DMAP / CH2Cl2 / 1 h / 0 °C 4.1: 77 percent / OsO4; NMO / 2-methyl-propan-2-ol; H2O / 24 h / 0 °C 5.1: p-TsOH*H2O / CH2Cl2 / 0.25 h / 0 °C 5.2: 99 percent / aq. HOAc / CH2Cl2 / 0.25 h / 0 °C 6.1: 62 percent / DBU / toluene / 1 h / 0 °C 7.1: 91 percent / DBU / toluene / 1 h / 0 °C View Scheme

5,7-bis(benzyloxy)-2-(4-(benzyloxy)phenyl)-3-hydroxy-4H-chromen-4-one (23405-70-1) → Kaempferol-3-O-(3,4-O-diacetyl-α-L-rhamnopyranoside) (77307-50-7)

Conditions	Yield
Multi-step reaction with 7 steps 1.1: 85 percent / PPh3 / Pd2(dba)3*CHCl3 / CH2Cl2 / 3 h / 0 °C 2.1: 73 percent / NaBH4 / CH2Cl2; methanol / 3 h / -78 °C 3.1: 156 mg / pyridine; DMAP / CH2Cl2 / 1 h / 0 °C 4.1: 77 percent / OsO4; NMO / 2-methyl-propan-2-ol; H2O / 24 h / 0 °C 5.1: p-TsOH*H2O / CH2Cl2 / 0.25 h / 0 °C 5.2: 99 percent / aq. HOAc / CH2Cl2 / 0.25 h / 0 °C 6.1: 62 percent / DBU / toluene / 1 h / 0 °C 7.1: 91 percent / DBU / toluene / 1 h / 0 °C View Scheme
Multi-step reaction with 2 steps 1: 60 percent / Ag2O / CH2Cl2 / 4 h / 20 °C 2: 94 percent / H2 / Pd(OH)2/C / tetrahydrofuran; methanol / 1 h View Scheme

3-((2S,6S)-5,6-dihydro-6-methyl-5-oxo-2H-pyran-2-yloxy)-5,7-bis(benzyloxy)-2-(4-(benzyloxy)phenyl)-4H-chromen-4-one (916069-02-8) → Kaempferol-3-O-(3,4-O-diacetyl-α-L-rhamnopyranoside) (77307-50-7)

Conditions

Yield

Multi-step reaction with 6 steps 1.1: 73 percent / NaBH4 / CH2Cl2; methanol / 3 h / -78 °C 2.1: 156 mg / pyridine; DMAP / CH2Cl2 / 1 h / 0 °C 3.1: 77 percent / OsO4; NMO / 2-methyl-propan-2-ol; H2O / 24 h / 0 °C 4.1: p-TsOH*H2O / CH2Cl2 / 0.25 h / 0 °C 4.2: 99 percent / aq. HOAc / CH2Cl2 / 0.25 h / 0 °C 5.1: 62 percent / DBU / toluene / 1 h / 0 °C 6.1: 91 percent / DBU / toluene / 1 h / 0 °C View Scheme

3-((2S,5R,6S)-5,6-dihydro-5-hydroxy-6-methyl-2H-pyran-2-yloxy)-5,7-bis(benzyloxy)-2-(4-(benzyloxy)phenyl)-4H-chromen-4-one (916069-03-9) → Kaempferol-3-O-(3,4-O-diacetyl-α-L-rhamnopyranoside) (77307-50-7)

Conditions	Yield
Multi-step reaction with 5 steps 1.1: 156 mg / pyridine; DMAP / CH2Cl2 / 1 h / 0 °C 2.1: 77 percent / OsO4; NMO / 2-methyl-propan-2-ol; H2O / 24 h / 0 °C 3.1: p-TsOH*H2O / CH2Cl2 / 0.25 h / 0 °C 3.2: 99 percent / aq. HOAc / CH2Cl2 / 0.25 h / 0 °C 4.1: 62 percent / DBU / toluene / 1 h / 0 °C 5.1: 91 percent / DBU / toluene / 1 h / 0 °C View Scheme

6-(5,7-bis(benzyloxy)-2-(4-(benzyloxy)phenyl)-4-oxo-4H-chromen-3-yloxy)-3,6-dihydro-2-methyl-2H-pyran-3-yl acetate (916069-05-1) → Kaempferol-3-O-(3,4-O-diacetyl-α-L-rhamnopyranoside) (77307-50-7)

Conditions	Yield
Multi-step reaction with 4 steps 1.1: 77 percent / OsO4; NMO / 2-methyl-propan-2-ol; H2O / 24 h / 0 °C 2.1: p-TsOH*H2O / CH2Cl2 / 0.25 h / 0 °C 2.2: 99 percent / aq. HOAc / CH2Cl2 / 0.25 h / 0 °C 3.1: 62 percent / DBU / toluene / 1 h / 0 °C 4.1: 91 percent / DBU / toluene / 1 h / 0 °C View Scheme

(2S,3R,4S,5R,6S)-6-((5,7-bis(benzyloxy)-2-(4-(benzyloxy)phenyl)-4-oxo-4H-chromen-3-yl)oxy)-4,5-dihydroxy-2-methyltetrahydro-2H-pyran-3-yl acetate (916069-06-2) → Kaempferol-3-O-(3,4-O-diacetyl-α-L-rhamnopyranoside) (77307-50-7)

Conditions	Yield
Multi-step reaction with 3 steps 1.1: p-TsOH*H2O / CH2Cl2 / 0.25 h / 0 °C 1.2: 99 percent / aq. HOAc / CH2Cl2 / 0.25 h / 0 °C 2.1: 62 percent / DBU / toluene / 1 h / 0 °C 3.1: 91 percent / DBU / toluene / 1 h / 0 °C View Scheme

(2S,3R,4R,5R,6S)-2-((5,7-bis(benzyloxy)-2-(4-(benzyloxy)phenyl)-4-oxo-4H-chromen-3-yl)oxy)-4-hydroxy-6-methyltetrahydro-2H-pyran-3,5-diyl diacetate (916069-07-3) → Kaempferol-3-O-(3,4-O-diacetyl-α-L-rhamnopyranoside) (77307-50-7)

Conditions	Yield
Multi-step reaction with 2 steps 1: 62 percent / DBU / toluene / 1 h / 0 °C 2: 91 percent / DBU / toluene / 1 h / 0 °C View Scheme

1-(2-furyl)-1-ethanone (1192-62-7) → Kaempferol-3-O-(3,4-O-diacetyl-α-L-rhamnopyranoside) (77307-50-7)

Conditions

Yield

Multi-step reaction with 10 steps 1.1: 92 percent / formic acid; Et3N / (R)-Ru(η6-mesitylene)-(S,S)-TsDPEN / CH2Cl2 / 24 h / 20 °C 2.1: 90 percent / NaHCO3; NaOAc*3H2O; NBS / tetrahydrofuran; H2O / 1 h / 0 °C 3.1: 60 percent / DMAP / CH2Cl2 / 12 h / -78 °C 4.1: 85 percent / PPh3 / Pd2(dba)3*CHCl3 / CH2Cl2 / 3 h / 0 °C 5.1: 73 percent / NaBH4 / CH2Cl2; methanol / 3 h / -78 °C 6.1: 156 mg / pyridine; DMAP / CH2Cl2 / 1 h / 0 °C 7.1: 77 percent / OsO4; NMO / 2-methyl-propan-2-ol; H2O / 24 h / 0 °C 8.1: p-TsOH*H2O / CH2Cl2 / 0.25 h / 0 °C 8.2: 99 percent / aq. HOAc / CH2Cl2 / 0.25 h / 0 °C 9.1: 62 percent / DBU / toluene / 1 h / 0 °C 10.1: 91 percent / DBU / toluene / 1 h / 0 °C View Scheme

5,7-bis(benzyloxy)-2-(4-(benzyloxy)phenyl)-4H-chromen-4-one (96333-59-4) → Kaempferol-3-O-(3,4-O-diacetyl-α-L-rhamnopyranoside) (77307-50-7)

Conditions	Yield
Multi-step reaction with 8 steps 1.1: DMSO; 3 Angstroem molecular sieves / acetone; CH2Cl2 / -20 - 0 °C 1.2: 50 percent / TsOH*H2O / CH2Cl2 / 1 h / 20 °C 2.1: 85 percent / PPh3 / Pd2(dba)3*CHCl3 / CH2Cl2 / 3 h / 0 °C 3.1: 73 percent / NaBH4 / CH2Cl2; methanol / 3 h / -78 °C 4.1: 156 mg / pyridine; DMAP / CH2Cl2 / 1 h / 0 °C 5.1: 77 percent / OsO4; NMO / 2-methyl-propan-2-ol; H2O / 24 h / 0 °C 6.1: p-TsOH*H2O / CH2Cl2 / 0.25 h / 0 °C 6.2: 99 percent / aq. HOAc / CH2Cl2 / 0.25 h / 0 °C 7.1: 62 percent / DBU / toluene / 1 h / 0 °C 8.1: 91 percent / DBU / toluene / 1 h / 0 °C View Scheme
Multi-step reaction with 3 steps 1.1: DMDO / CH2Cl2; acetone / 0 °C 1.2: 78 percent Turnov. / pTsOH / CH2Cl2 / 0.5 h / 0 °C 2.1: 60 percent / Ag2O / CH2Cl2 / 4 h / 20 °C 3.1: 94 percent / H2 / Pd(OH)2/C / tetrahydrofuran; methanol / 1 h View Scheme

5,7-Dihydroxy-2-(4-hydroxy-phenyl)-chroman-4-on (480-41-1) → Kaempferol-3-O-(3,4-O-diacetyl-α-L-rhamnopyranoside) (77307-50-7)

Conditions

Yield

Multi-step reaction with 10 steps 1.1: 75 percent / K2CO3 / acetone / 6 h / Heating 2.1: 76 percent / I2 / dimethylsulfoxide / 24 h / 110 °C 3.1: DMSO; 3 Angstroem molecular sieves / acetone; CH2Cl2 / -20 - 0 °C 3.2: 50 percent / TsOH*H2O / CH2Cl2 / 1 h / 20 °C 4.1: 85 percent / PPh3 / Pd2(dba)3*CHCl3 / CH2Cl2 / 3 h / 0 °C 5.1: 73 percent / NaBH4 / CH2Cl2; methanol / 3 h / -78 °C 6.1: 156 mg / pyridine; DMAP / CH2Cl2 / 1 h / 0 °C 7.1: 77 percent / OsO4; NMO / 2-methyl-propan-2-ol; H2O / 24 h / 0 °C 8.1: p-TsOH*H2O / CH2Cl2 / 0.25 h / 0 °C 8.2: 99 percent / aq. HOAc / CH2Cl2 / 0.25 h / 0 °C 9.1: 62 percent / DBU / toluene / 1 h / 0 °C 10.1: 91 percent / DBU / toluene / 1 h / 0 °C View Scheme

L-aculose (247244-65-1) → Kaempferol-3-O-(3,4-O-diacetyl-α-L-rhamnopyranoside) (77307-50-7)

Conditions

Yield

Multi-step reaction with 8 steps 1.1: 60 percent / DMAP / CH2Cl2 / 12 h / -78 °C 2.1: 85 percent / PPh3 / Pd2(dba)3*CHCl3 / CH2Cl2 / 3 h / 0 °C 3.1: 73 percent / NaBH4 / CH2Cl2; methanol / 3 h / -78 °C 4.1: 156 mg / pyridine; DMAP / CH2Cl2 / 1 h / 0 °C 5.1: 77 percent / OsO4; NMO / 2-methyl-propan-2-ol; H2O / 24 h / 0 °C 6.1: p-TsOH*H2O / CH2Cl2 / 0.25 h / 0 °C 6.2: 99 percent / aq. HOAc / CH2Cl2 / 0.25 h / 0 °C 7.1: 62 percent / DBU / toluene / 1 h / 0 °C 8.1: 91 percent / DBU / toluene / 1 h / 0 °C View Scheme

(S)-1-(2-furanyl)ethanol (4208-64-4, 27948-61-4, 106565-48-4, 112653-32-4) → Kaempferol-3-O-(3,4-O-diacetyl-α-L-rhamnopyranoside) (77307-50-7)

Conditions

Yield

Multi-step reaction with 9 steps 1.1: 90 percent / NaHCO3; NaOAc*3H2O; NBS / tetrahydrofuran; H2O / 1 h / 0 °C 2.1: 60 percent / DMAP / CH2Cl2 / 12 h / -78 °C 3.1: 85 percent / PPh3 / Pd2(dba)3*CHCl3 / CH2Cl2 / 3 h / 0 °C 4.1: 73 percent / NaBH4 / CH2Cl2; methanol / 3 h / -78 °C 5.1: 156 mg / pyridine; DMAP / CH2Cl2 / 1 h / 0 °C 6.1: 77 percent / OsO4; NMO / 2-methyl-propan-2-ol; H2O / 24 h / 0 °C 7.1: p-TsOH*H2O / CH2Cl2 / 0.25 h / 0 °C 7.2: 99 percent / aq. HOAc / CH2Cl2 / 0.25 h / 0 °C 8.1: 62 percent / DBU / toluene / 1 h / 0 °C 9.1: 91 percent / DBU / toluene / 1 h / 0 °C View Scheme

(E)-1-(2,4-bis(benzyloxy)-6-hydroxyphenyl)-3-(4-(benzyloxy)phenyl)prop-2-en-1-one (88607-79-8) → Kaempferol-3-O-(3,4-O-diacetyl-α-L-rhamnopyranoside) (77307-50-7)

Conditions	Yield
Multi-step reaction with 9 steps 1.1: 76 percent / I2 / dimethylsulfoxide / 24 h / 110 °C 2.1: DMSO; 3 Angstroem molecular sieves / acetone; CH2Cl2 / -20 - 0 °C 2.2: 50 percent / TsOH*H2O / CH2Cl2 / 1 h / 20 °C 3.1: 85 percent / PPh3 / Pd2(dba)3*CHCl3 / CH2Cl2 / 3 h / 0 °C 4.1: 73 percent / NaBH4 / CH2Cl2; methanol / 3 h / -78 °C 5.1: 156 mg / pyridine; DMAP / CH2Cl2 / 1 h / 0 °C 6.1: 77 percent / OsO4; NMO / 2-methyl-propan-2-ol; H2O / 24 h / 0 °C 7.1: p-TsOH*H2O / CH2Cl2 / 0.25 h / 0 °C 7.2: 99 percent / aq. HOAc / CH2Cl2 / 0.25 h / 0 °C 8.1: 62 percent / DBU / toluene / 1 h / 0 °C 9.1: 91 percent / DBU / toluene / 1 h / 0 °C View Scheme
Multi-step reaction with 4 steps 1.1: 72 percent / I2 / dimethylsulfoxide / 140 °C 2.1: DMDO / CH2Cl2; acetone / 0 °C 2.2: 78 percent Turnov. / pTsOH / CH2Cl2 / 0.5 h / 0 °C 3.1: 60 percent / Ag2O / CH2Cl2 / 4 h / 20 °C 4.1: 94 percent / H2 / Pd(OH)2/C / tetrahydrofuran; methanol / 1 h View Scheme

phenyl 2-O-benzyl-1-thio-α-L-rhamnopyranoside (849938-16-5) → Kaempferol-3-O-(3,4-O-diacetyl-α-L-rhamnopyranoside) (77307-50-7)

Conditions	Yield
Multi-step reaction with 4 steps 1: 100 percent / Et3N; DMAP / CH2Cl2 / 20 °C 2: 84 percent / Br2 / CH2Cl2 / 1 h / 0 °C 3: 60 percent / Ag2O / CH2Cl2 / 4 h / 20 °C 4: 94 percent / H2 / Pd(OH)2/C / tetrahydrofuran; methanol / 1 h View Scheme

3,4-di-O-acetyl-2-O-benzyl-α-L-rhamnopyranosyl bromide (849938-23-4) → Kaempferol-3-O-(3,4-O-diacetyl-α-L-rhamnopyranoside) (77307-50-7)

Conditions	Yield
Multi-step reaction with 2 steps 1: 60 percent / Ag2O / CH2Cl2 / 4 h / 20 °C 2: 94 percent / H2 / Pd(OH)2/C / tetrahydrofuran; methanol / 1 h View Scheme

phenyl 3,4-di-O-acetyl-2-O-benzyl-1-thio-α-L-rhamnopyranoside (849938-20-1) → Kaempferol-3-O-(3,4-O-diacetyl-α-L-rhamnopyranoside) (77307-50-7)

Conditions	Yield
Multi-step reaction with 3 steps 1: 84 percent / Br2 / CH2Cl2 / 1 h / 0 °C 2: 60 percent / Ag2O / CH2Cl2 / 4 h / 20 °C 3: 94 percent / H2 / Pd(OH)2/C / tetrahydrofuran; methanol / 1 h View Scheme

naringenin (480-41-1) → Kaempferol-3-O-(3,4-O-diacetyl-α-L-rhamnopyranoside) (77307-50-7)

Conditions	Yield
Multi-step reaction with 5 steps 1.1: 81 percent / K2CO3 / acetone / Heating 2.1: 72 percent / I2 / dimethylsulfoxide / 140 °C 3.1: DMDO / CH2Cl2; acetone / 0 °C 3.2: 78 percent Turnov. / pTsOH / CH2Cl2 / 0.5 h / 0 °C 4.1: 60 percent / Ag2O / CH2Cl2 / 4 h / 20 °C 5.1: 94 percent / H2 / Pd(OH)2/C / tetrahydrofuran; methanol / 1 h View Scheme

C85H88O11Si3 → Kaempferol-3-O-(3,4-O-diacetyl-α-L-rhamnopyranoside) (77307-50-7)

C89H96O12Si4 → Kaempferol-3-O-(3,4-O-diacetyl-α-L-rhamnopyranoside) (77307-50-7)

Conditions	Yield
With tetrabutyl ammonium fluoride In tetrahydrofuran

acetic anhydride (108-24-7) + Kaempferol-3-O-(3,4-O-diacetyl-α-L-rhamnopyranoside) (77307-50-7) → Acetic acid (2S,3R,4R,5S,6S)-4,5-diacetoxy-2-[7-acetoxy-2-(4-acetoxy-phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yloxy]-6-methyl-tetrahydro-pyran-3-yl ester

Conditions	Yield
With pyridine at 23℃; for 1h;

acetic anhydride (108-24-7) + Kaempferol-3-O-(3,4-O-diacetyl-α-L-rhamnopyranoside) (77307-50-7) → Peracetylated-SL0101 (72165-31-2)

Conditions	Yield
With pyridine

Kaempferol-3-O-(3,4-O-diacetyl-α-L-rhamnopyranoside) (77307-50-7) → kaempferol 3-rhamnoside (482-39-3, 22334-39-0, 28978-08-7)

Conditions	Yield
With sodium hydroxide In methanol at 23℃; for 0.333333h;	9 mg
With potassium carbonate In methanol

Upstream product

• 1192-62-7 1-(2-furyl)-1-ethanone 
• 96333-59-4 5,7-bis(benzyloxy)-2-(4-(benzyloxy)phenyl)-4H-chromen-4-one 
• 480-41-1 naringenin 
• 849938-20-1 phenyl 3,4-di-O-acetyl-2-O-benzyl-1-thio-α-L-rhamnopyranoside 
• 849938-23-4 3,4-di-O-acetyl-2-O-benzyl-α-L-rhamnopyranosyl bromide 
• 849938-16-5 phenyl 2-O-benzyl-1-thio-α-L-rhamnopyranoside 
• 88607-79-8 (E)-1-(2,4-bis(benzyloxy)-6-hydroxyphenyl)-3-(4-(benzyloxy)phenyl)prop-2-en-1-one 
• 247244-65-1 L-aculose 
• 480-41-1 5,7-Dihydroxy-2-(4-hydroxy-phenyl)-chroman-4-on 
• 916069-07-3 (2S,3R,4R,5R,6S)-2-((5,7-bis(benzyloxy)-2-(4-(benzyloxy)phenyl)-4-oxo-4H-chromen-3-yl)oxy)-4-hydroxy-6-methyltetrahydro-2H-pyran-3,5-diyl diacetate 
• 916069-06-2 (2S,3R,4S,5R,6S)-6-((5,7-bis(benzyloxy)-2-(4-(benzyloxy)phenyl)-4-oxo-4H-chromen-3-yl)oxy)-4,5-dihydroxy-2-methyltetrahydro-2H-pyran-3-yl acetate 
• 916069-05-1 6-(5,7-bis(benzyloxy)-2-(4-(benzyloxy)phenyl)-4-oxo-4H-chromen-3-yloxy)-3,6-dihydro-2-methyl-2H-pyran-3-yl acetate 
• 916069-03-9 3-((2S,5R,6S)-5,6-dihydro-5-hydroxy-6-methyl-2H-pyran-2-yloxy)-5,7-bis(benzyloxy)-2-(4-(benzyloxy)phenyl)-4H-chromen-4-one 
• 916069-02-8 3-((2S,6S)-5,6-dihydro-6-methyl-5-oxo-2H-pyran-2-yloxy)-5,7-bis(benzyloxy)-2-(4-(benzyloxy)phenyl)-4H-chromen-4-one 

Downstream Products

• 482-39-3 kaempferol 3-rhamnoside 

Relevant academic research and scientific papers

De novo asymmetric syntheses of SL0101 and its analogues via a palladium-catalyzed glycosylation

(Chemical Equation Presented) The enantioselective syntheses of naturally occurring kaempferol glycoside SL0101 (1a) and its analogues 1b-e, as well as their enantiomers, have been achieved in 7-10 steps. The routes rely upon a diastereoselective palladium-catalyzed glycosylation, ketone reduction, and dihydroxylation to introduce the rhamno-stereochemistry. The asymmetry of the sugar moiety of these kaempferol glycosides was derived from Noyori reduction of an acylfuran. An acetyl group shift from an axial (C-2) to equatorial position (C-3) under basic conditions was also described.

Synthesis of a potent and selective inhibitor of p90 Rsk

(Chemical Equation Presented) The synthesis of the naturally occurring kaempferol glycoside SL0101 has been accomplished, as has its biochemical evaluation. SL0101 exhibits selective and potent p90 Rsk inhibitory activity at nanomolar concentrations without inhibiting the function of upstream kinases such as MEK, Raf, or PKC. The synthesis verified the structural assignment of the natural product and has provided access to material sufficient for detailed biological evaluation.

RSK INHIBITORS AND THERAPEUTIC USES THEREOF

The present invention is directed to novel compounds and compositions that have Rsk specific inhibitory activity. In addition, inhibition of Rsk by the present compounds has been discovered to halt the proliferation of cancer cell lines while having little effect on the proliferation rate of normal cells. Therefore, the present invention identifies Rsk as a target for therapeutic intervention in diseased states in which the disease or the symptoms can be ameliorated by inhibition of Rsk catalytic activity.